Glenmark Pharma launches 'Teneligliptin + Pioglitazone' fixed-dose combination drug

25 Apr 2022 Evaluate

Glenmark Pharmaceuticals has launched a novel fixed-dose combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) plus Pioglitazone (15 mg), to be taken once a day.

Glenmark is the first company in India to market the innovative FDC of Teneligliptin plus Pioglitazone, which is approved by the DCGI (Drug Controller General of India). This fixed dose combination will be useful for patients who require treatment with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control reducing Insulin Resistance.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1988.65 -4.05 (-0.20%)
29-Jan-2026 10:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.00
Dr. Reddys Lab 1194.50
Cipla 1312.45
Zydus Lifesciences 885.00
Lupin 2102.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×